Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantum
about
CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffoldsStructural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Structural complex of sterol 14 -demethylase (CYP51) with 14 -methylenecyclopropyl- 7-24, 25-dihydrolanosterolAntitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite GrowthAntifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1Complexes of Trypanosoma cruzi Sterol 14 -Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: STRUCTURAL BASIS FOR PATHOGEN SELECTIVITYExpanding the Binding Envelope of CYP51 Inhibitors TargetingTrypanosoma cruziwith 4-Aminopyridyl-Based Sulfonamide DerivativesFunctional and structural characterisation of a viral cytochrome b5The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking InvestigationsTargeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylaseSterol biosynthesis is required for heat resistance but not extracellular survival in leishmaniaNovel sterol metabolic network of Trypanosoma brucei procyclic and bloodstream formsSterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasisFungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens.Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14α-demethylase (CYP51)Resistance to antifungals that target CYP51.Sterols in spermatogenesis and sperm maturation.Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionDrug strategies targeting CYP51 in neglected tropical diseasesDynamics of CYP51: implications for function and inhibitor design.Interactions of antiparasitic sterols with sterol 14α-demethylase (CYP51) of human pathogensAzole fungicides - understanding resistance mechanisms in agricultural fungal pathogens.Azole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51)Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosaStructure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs.VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.Fluorinated Sterols Are Suicide Inhibitors of Ergosterol Biosynthesis and Growth in Trypanosoma brucei.The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design.Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana.Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis.Targeting CYP51 for drug design by the contributions of molecular modeling.New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruziIn-silico Leishmania target selectivity of antiparasitic terpenoids.Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design.5-Formylcytosine to cytosine conversion by C-C bond cleavage in vivo.Antitrypanosomal and antileishmanial activity of prenyl-1,2,3-triazoles.
P2860
Q24605691-084B5391-1864-457C-A5F8-95B6F4E9079FQ27324352-9A642203-EAEC-4C4B-94B2-6EFAAC7D12DAQ27675909-9B14B058-8F8F-48AE-A411-1C442F89967EQ27676649-DAD1BED6-AE39-4D1D-B9BC-ECA75D1F9756Q27677470-52A052A1-7A7B-417C-92FF-D97D363CB11BQ27679983-1C173E8A-A1A5-4337-B19B-1F08B59B8848Q27683570-E849F6CF-FB1A-429A-80AE-0ED81651518DQ27686957-E2C8D50F-2063-41F7-A851-FE0A4B4DCE3FQ28066944-CD9251B1-D41B-445C-BE4C-035C331EB3B8Q28544037-14912B31-EB42-4C9C-8BBA-350260115111Q28544093-7A9C7DDF-4E2C-4ED7-A5DB-C8AEA1E3C423Q28714212-3E3B3F87-10F6-42F9-A461-C2E38DE9C5A3Q28727454-8075ECA4-A67A-43F9-B22D-319179BC07ACQ30318077-3F4BFD6C-2ED7-469A-8AF1-EA1844B94317Q34261359-7A557F86-36E6-47E6-AEA4-9B7B03CC971CQ34276700-CBB60E9A-83D0-45AE-A54A-775C6CEEA7E4Q34307905-69AEE681-0529-422C-B1F9-E6DB48BFB266Q34614864-67288026-0DF5-4D4A-B38C-321CB606CDE3Q34622554-CA89D463-7E93-49D3-AEC4-AC68CD098156Q35110082-90E3E915-3FEE-4F2B-B812-CED799D18091Q35541487-9468B388-11A3-4738-B84F-E2FB9E27D28CQ35614936-A652900A-4ED6-48EF-81E7-2618648B8517Q35642775-E44F3733-A6BF-4310-91EB-120A86A92F9CQ36049722-9A684A63-9EF9-49FF-8626-345256D51E7AQ36093075-392BFA4C-2887-46CC-9993-4B2C3112A550Q36148993-268B2755-EB0E-4112-B4BF-B627C12CA011Q36219533-8E08F396-91B8-42A9-80E4-314A2488A388Q36366481-35612092-0462-4BC0-9219-21C3B875794FQ36399175-050AE1CB-D4F9-4259-856A-DBB4D166E967Q36407342-56744E5E-95D4-41BB-B777-A60F909FBC29Q36571788-322423B7-48B0-4DC1-9670-DF8F1C613133Q37401820-A3F05308-345C-4041-B6C1-EA412E7A5C58Q38750944-3EDCCF52-3A43-440D-BD4E-321A998E207CQ38917135-F8245E6E-442D-41E2-8337-FA394B2BA83BQ39012627-B502F504-8827-4C0D-BA25-F2D5F88310EEQ39318097-6A903C12-B873-46C9-A6FD-2FBBB6A4BA5CQ42266154-8E2854EE-3933-4486-AEE5-C39E00A7C4E0Q47363859-27B222A7-C460-497E-899D-D3B37B0F26BDQ49376507-5263B738-7043-4E8B-903C-300EF1DED5F6
P2860
Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantum
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@ast
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@en
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@nl
type
label
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@ast
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@en
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@nl
prefLabel
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@ast
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@en
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@nl
P2093
P2860
P921
P3181
P356
P1476
Substrate Preferences and Cata ...... YP51) from Leishmania infantum
@en
P2093
Galina I Lepesheva
Jialin Liu
Michael R Waterman
Tatiana Y Hargrove
W David Nes
P2860
P304
P3181
P356
10.1074/JBC.M111.237099
P407
P577
2011-07-29T00:00:00Z